Please login to the form below

Not currently logged in
Email:
Password:

empagliflozin

This page shows the latest empagliflozin news and features for those working in and with pharma, biotech and healthcare.

FDA’s year-end approvals take annual tally to 46

FDA’s year-end approvals take annual tally to 46

established drugs Johnson &Johnson’s first-to-market blockbuster Invokana (canagliflozin) - which brought in more than $1.2bn last year - fast-gaining rival Jardiance (empagliflozin) from Eli Lilly and Boehringer Ingelheim

Latest news

More from news
Approximately 15 fully matching, plus 61 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics